October 10, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Arrowhead Research Corp (NASDAQ:ARWR) shares over potential securities laws violations by Arrowhead Research and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Arrowhead Research Corp (NASDAQ:ARWR) concerning whether a series of statements by Arrowhead Research regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. Arrowheads pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. Shares of Arrowhead Research Corp (NASDAQ:ARWR) grew from $9.79 per share in May 2014 to as high as $16.96 per share in September 2014.

On October 8, 2014, Arrowhead Research Corp announced that data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B (HBV) infection, will be presented in the late-breaking poster session at the 2014 American Association for the Study of Liver Diseases (AASLD) Liver Meeting being held on November 7-11, 2014, in Boston.
On that same day, an article was published on that claimed Arrowhead Research CEO Chris Anzalone and his team knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded 0.2-log and 0.3-log reductions in hepatitis B viral load.

On October 9, 2014, Arrowhead Research Corp issued an open letter to shareholders from President and CEO of Arrowhead Research Corp.

Shares of Arrowhead Research Corp (NASDAQ:ARWR) declined from $13.01 per share on October 7, 2014, to as low as $5.47 per share on October 8, 2014, respectively $6.75 per share on October 9, 2014.